Trials / Completed
CompletedNCT02453009
Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer
CHemotherapy Plus Enzalutamide In First Line Therapy for Castration Resistant prOstate caNcer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 246 (actual)
- Sponsor
- Santa Chiara Hospital · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to verify if the addition of enzalutamide to docetaxel is able to improve the disease control in first line CRPC patients.
Detailed description
CHEIRON trial is a phase II randomized study comparing docetaxel plus enzalutamide to docetaxel alone as first line for castration resistant prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | Pharmaceutical form:solution Route of administration: intravenous |
| DRUG | Prednisone | Pharmaceutical form:tablet Route of administration: oral |
| DRUG | Enzalutamide | Pharmaceutical form : soft gelatin capsules Route of administration: oral |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2018-04-01
- Completion
- 2019-04-01
- First posted
- 2015-05-25
- Last updated
- 2024-05-30
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT02453009. Inclusion in this directory is not an endorsement.